FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer-Reference-Cited by-同舟云学术

FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer

Published:2018-03 Issue:10 Volume:97 Page:e0097
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Chen Datian,Li Li,Zhang Xiang,Gao Guangyi,Shen Lili,Hu Jing,Yang Mi,Liu Baorui,Qian Xiaoping

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference43 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

2. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer;Van Cutsem;N Engl J Med,2009

3. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer;Amado;J Clin Oncol,2008

4. K-ras mutations and benefit from cetuximab in advanced colorectal cancer;Karapetis;N Engl J Med,2008

5. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis;Vale;Cancer Treat Rev,2012

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer;JAMA;2023-04-18

2. Efficacy and safety of triplet chemotherapy plus anti-EGFR agents in metastatic colorectal cancer: a systematic review and meta-analysis;World Journal of Surgical Oncology;2022-08-15

3. Colorectal Cancer, Liver Metastases and Biotherapies;Biomedicines;2021-07-26

4. Organoids and Colorectal Cancer;Cancers;2021-05-28

5. Effectiveness of first‐line cetuximab in wild‐type RAS metastatic colorectal cancer according to tumour BRAF mutation status from the EREBUS cohort;British Journal of Clinical Pharmacology;2020-09-15